{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016388","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.516540+00:00","generated_at":"2026-06-15T05:27:33.812867+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lineage Cell Therapeutics Q1 net loss $4.4M, cash $46.8M; OpRegen phase 2a enrolling","bullets":["Revenue $2.4M, down 54% YoY from $5.2M due to lower Roche collaboration revenue.","Net loss improved to $4.4M ($0.03/share) from $7.1M ($0.04/share) in Q1 2022.","Cash equivalents and marketable securities $46.8M; expected to fund operations into Q3 2024.","OpRegen Phase 2a for GA secondary to AMD continues enrolling; new sites expected in 2023.","OPC1 granted US patent expiring no earlier than 2040; Type B meeting with FDA planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016388","json":"https://secwatch.observer/filing/0001493152-23-016388.json","markdown":"https://secwatch.observer/filing/0001493152-23-016388.md","text":"https://secwatch.observer/filing/0001493152-23-016388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315223016388/0001493152-23-016388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315223016388/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:27:33.812867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}